Digital health company has announced the initiation of a DARPA-backed study that will use the company's minimally invasive injectable biosensor technology as a platform to potentially assist in the early detection of influenza outbreaks. The study will examine how sensors monitoring physiological status - including Profusa'a Lumee Oxygen Platform , which measures tissue oxygen levels - provide potential indicators of human response to infection or exposure to disease in healthy volunteers.